Loading stock data…
$7.91+0.09 (+1.15%)
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
DiaMedica Therapeutics Inc. in the Healthcare sector is trading at $7.91 with a market capitalization of $349M. Wall Street consensus targets $15.50 (4 analysts), implying a +96.0% move over the next 12 months. The stock is currently 24% below its 52-week high of $10.42, remaining 11.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.50M↓ | -$10.48M↓ | -$9.21M↓ | -$9.03M↓ | -$8.01M |
| Net Income | -$10.14M↓ | -$10.04M↓ | -$8.74M↓ | -$8.62M↓ | -$7.70M |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kal...